TABLE 2.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | | |
|  | **Baseline** | | **8 Weeks** | | **Change** | | **ANCOVA** | | |
|  | **n** | **Mean (SD)** | **n** | **Mean (SD)** | **n** | **Mean (SD)** | **Estimate\*** | **95%CI** | **p** |
| **GLVEF (%)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 39.4 (7.5) | 14 | 45.9 (5.8) | 14 | 6.5 (6.3) |  | ref |  |
| LD-IGF1 1.5 ng | 13 | 41.2 (9.5) | 15 | 48.5 (13.1) | 13 | 8.2 (7.5) | 0.87 | (-4.627 to 6.366) | 0.758 |
| LD-IGF1 15 ng | 15 | 44.9 (8) | 14 | 50.2 (9.6) | 14 | 4.7 (6.2) | -1.96 | (-7.532 to 3.612) | 0.495 |
| **LVEDV Index (ml/m2)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 96 (16.2) | 14 | 114.5 (20.6) | 14 | 18.5 (14.2) |  | ref |  |
| LD-IGF1 1.5 ng | 13 | 98.6 (17.3) | 15 | 105.1 (22.4) | 13 | 9.1 (18) | -4.735 | (-18.672 to 9.203) | 0.51 |
| LD-IGF1 15 ng | 15 | 93.6 (9.7) | 14 | 95 (24) | 14 | 2.3 (18.9) | -10.219 | (-24.043 to 3.606) | 0.157 |
| **LVESV Index (ml/m2)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 58.7 (15) | 14 | 62.2 (14.6) | 14 | 3.6 (10.3) |  | ref |  |
| LD-IGF1 1.5 ng | 13 | 58.8 (17.3) | 15 | 55.4 (21.5) | 13 | -2.6 (15.5) | -3.47 | (-14.476 to 7.535) | 0.541 |
| LD-IGF1 15 ng | 15 | 51.8 (10.4) | 14 | 49.5 (19.2) | 14 | -1.2 (13.4) | -1.864 | (-12.889 to 9.161) | 0.742 |
| **LV Mass Index (g/m2)** |  |  |  |  |  |  |  |  |  |
| Placebo | 10 | 85.8 (17) | 12 | 85 (14.8) | 9 | 0.5 (8.6) |  | ref |  |
| LD-IGF1 1.5 ng | 9 | 93 (17.1) | 12 | 90.8 (7.2) | 8 | -2 (13.4) | 0.575 | (-10.34 to 11.49) | 0.919 |
| LD-IGF1 15 ng | 15 | 92.5 (19.9) | 13 | 75.9 (18.4) | 13 | -17 (13.4) | -15.452 | (-25.461 to -5.443) | 0.006 |
| **Stroke Volume (ml)** |  |  |  |  |  |  |  |  |  |
| Placebo | 14 | 71.4 (20.3) | 14 | 99.9 (26.1) | 14 | 28.4 (17.8) |  | ref |  |
| LD-IGF1 1.5 ng | 13 | 74.2 (17.4) | 15 | 92 (27) | 13 | 21.6 (17.2) | -4.221 | (-17.001 to 8.56) | 0.522 |
| LD-IGF1 15 ng | 15 | 83.6 (15.7) | 14 | 94.8 (14.9) | 14 | 10.9 (14.1) | -11.234 | (-24.431 to 1.964) | 0.105 |
| **Late CE\*\*** |  |  |  |  |  |  |  |  |  |
| Placebo | 10 | 56.2 (29) | 12 | 49.1 (19.3) | 9 | -12.5 (20.4) |  | ref |  |
| LD-IGF1 1.5 ng | 10 | 59.2 (34.3) | 12 | 47.4 (22.4) | 9 | -12.4 (21.2) | 3.805 | (-14.505 to 22.115) | 0.687 |
| LD-IGF1 15 ng | 15 | 56.8 (48.7) | 13 | 34.5 (29.6) | 13 | -18.2 (26.2) | -6.391 | (-25.642 to 12.861) | 0.52 |
|  | | | | | | | | | |

\* Expressed as differences (vs. Placebo) in adjusted means (ANCOVA, adjusted for baseline outcome, diabetes status, and TIMI flow prior to PCI) with corresponding 95% Cis and p-value from the two sided test of no difference. \*\* Late CE model not adjusted for baseline late CE.